bioRxivCancer Biology
Plasticity of extrachromosomal and intrachromosomal BRAF amplifications in mediating targeted therapy dosage challenges
K. Song, J. K. Minami, W. P. Crosson, J. Salazar, E. Pazol, N. T. Senaratne, N. Rao, K. Paraiso, T. G. Graeber
Abstract
Cancer cells display two modes of focal amplifications (FAs), extrachromosomal DNA/double-minutes (ecDNA/DMs) and intrachromosomal homogenously staining regions (HSRs). Understanding the plasticity of these two modes is critical for preventing targeted therapy resistance. We developed a combined BRAF plus MEK inhibitor resistance melanoma model that bears high BRAF amplifications through both DM and HSR modes, and investigated FA dynamics in the context of drug resistance plasticity. Cells harboring FAs displayed mode switching between DMs and HSRs, from both de novo genetic changes and selection of preexisting subpopulations. We found that copy number plasticity is not exclusive to DMs. Single cell-derived clones with HSRs also exhibit BRAF copy number and corresponding HSR length plasticity that allows them to respond to dose reduction and recover from drug addiction. Upon kinase inhibitor escalation, we observed reproducible selection for cells with BRAF kinase domain duplications residing on DMs. In sum, the plasticity of FAs allows cancer cells to respond to drug dose changes through a myriad of mechanisms. These mechanisms include increases or decreases in DMs, shortening of HSRs, acquisition of secondary resistance mechanisms, and expression of alternative slicing oncogene variants. These results highlight the challenges in targeting the cellular vulnerabilities tied to focal amplifications. Statement of SignificanceUnderstanding the dynamics of oncogene amplifications is critical for appreciating tumorigenesis and preventing anticancer drug resistance. We found melanoma cells harboring BRAF amplifications in either DM or HSR formats to have high plasticity under different kinase inhibitor dosage challenges with evidence supporting de novo alterations, clonal selection, and coupling to additional resistance mechanisms. In in the absence of DMs, HSRs can offer comparable levels of plasticity as DMs.
- organism: human
- assay: DNA methylation
- assay: whole-genome sequencing
- research focus: cancer & tumor microenvironment
- research focus: clustering
- research focus: differential expression
- research focus: drug response / drug discovery
- approach: experimental assay
- approach: statistical model
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- BRAF inhibitor resistance confers increased sensitivity to mitotic inhibitors
S. Misek, T. Dexheimer, … K. A. Gallo·bioRxiv·Apr 15, 2021
- Sporadic ERK pulses drive non-genetic resistance in drug-adapted BRAFV600E melanoma cells
L. Gerosa, C. Chidley, … P. K. Sorger·bioRxiv·Sep 8, 2019
- Resistance to BRAF inhibitors drives melanoma sensitivity to Chk1 inhibition
Danielle Gonçalves de Carvalho, Juliana C.N. Kenski, … Patrícia A. Possik·Pharmacological ResearchPeer-reviewed·May 23, 2025
- DNA replication during acute MEK inhibition drives acquisition of resistance through amplification of the BRAF oncogene
Prasanna Channathodiyil, Kieron May, … Jonathan M. Houseley·NAR CancerPeer-reviewed·Sep 28, 2022
- The dynamics of ERK signaling in melanoma, and the response to BRAF or MEK inhibition, are cell cycle dependent.
Chloe M. Simpson, Nicola Ferrari, … Chris Bakal·bioRxiv·Aug 13, 2018
- Rapidly induced drug adaptation mediates escape from BRAF inhibition in single melanoma cells
c. yang, C. Tian, … S. L. Spencer·bioRxiv·Mar 15, 2020